drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (adoptive T-cell therapy)
drug_description
Ex vivo–manufactured, polyclonal TCR-mediated tumor antigen–specific CTLs expanded in G-Rex bioreactors to enrich early-memory phenotypes; administered as adoptive T-cell therapy targeting pediatric solid tumors.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Cytotoxic
drug_category
TCR SELECTED T CELLS
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ex vivo–expanded, polyclonal cytotoxic T lymphocytes with native TCRs recognize shared tumor-associated antigens presented by HLA class I on pediatric solid tumor cells, become activated, and mediate perforin/granzyme-dependent killing with supportive cytokine secretion; enrichment for early-memory phenotypes enhances in vivo persistence and antitumor activity after adoptive transfer.
drug_name
Tumor antigen–specific cytotoxic T lymphocytes (CTLs)
nct_id_drug_ref
NCT07240207